<DOC>
	<DOCNO>NCT01650129</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial investigate safety efficacy biphasic insulin aspart ( BIAsp ) 50 ( NN-X14Mix50 ) compare biphasic human insulin ( BHI ) 50 subject type 2 diabetes .</brief_summary>
	<brief_title>Safety Efficacy Biphasic Insulin Aspart 50 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Subjects type 2 diabetes Subjects insulin treat least 24 week HbA1c maximum 11.0 % Body mass index ( BMI ) 30.0 kg/m^2 Patients skill selfinjection insulin , able willing perform selfmonitoring blood glucose ( SMBG ) able take measure hypoglycaemic episode Recurrent severe hypoglycaemia Subjects proliferative retinopathy preproliferative retinopathy diagnose within last 12 week , receive photocoagulation therapy within last one year Impaired hepatic function Impaired renal function Cardiac diseases Uncontrolled hypertension Subjects history severe allergic severe hypersensitive reaction Total daily insulin dose least 100 IU Treatment oral hypoglycaemic agentsvwithin last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>